A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for older patients with AML

Amer M. Zeidan, Isaac Boss, C. L. Beach, Wilbert B. Copeland, Ethan Thompson, Brian A. Fox, Vanessa E. Hasle, Andrzej Hellmann, David C. Taussig, Mar Tormo, Maria Teresa Voso, James Cavenagh, Tim O’Connor, Alessandro Previtali, Shelonitda Rose, Lewis R. Silverman

Research output: Contribution to journalArticlepeer-review

39 Scopus citations

Fingerprint

Dive into the research topics of 'A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for older patients with AML'. Together they form a unique fingerprint.

Medicine & Life Sciences